Business Description
Huaren Pharmaceutical Co Ltd
NAICS : 325411
ISIN : CNE100000SW1
Share Class Description:
SZSE:300110: Class ACompare
Compare
Traded in other countries / regions
300110.China IPO Date
2010-08-25Description
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | 6.56 | |||||
| Interest Coverage | 4.2 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.3 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.5 | |||||
| 3-Year EBITDA Growth Rate | 21 | |||||
| 3-Year EPS without NRI Growth Rate | 23.4 | |||||
| 3-Year Book Growth Rate | 6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.66 | |||||
| 9-Day RSI | 36.92 | |||||
| 14-Day RSI | 40.62 | |||||
| 6-1 Month Momentum % | 25.24 | |||||
| 12-1 Month Momentum % | -8.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | |||||
| Quick Ratio | 1.56 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 126.22 | |||||
| Days Sales Outstanding | 154.42 | |||||
| Days Payable | 51.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.58 | |||||
| Dividend Payout Ratio | 0.18 | |||||
| 3-Year Dividend Growth Rate | 28.1 | |||||
| Forward Dividend Yield % | 0.58 | |||||
| 5-Year Yield-on-Cost % | 0.57 | |||||
| Shareholder Yield % | 6.61 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.06 | |||||
| Operating Margin % | 15.41 | |||||
| Net Margin % | 9.81 | |||||
| FCF Margin % | 23.99 | |||||
| ROE % | 5.39 | |||||
| ROA % | 2.91 | |||||
| ROIC % | 4.2 | |||||
| ROC (Joel Greenblatt) % | 14.53 | |||||
| ROCE % | 6.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.39 | |||||
| PE Ratio without NRI | 30.09 | |||||
| Shiller PE Ratio | 44 | |||||
| Price-to-Owner-Earnings | 39.12 | |||||
| PEG Ratio | 1.58 | |||||
| PS Ratio | 2.77 | |||||
| PB Ratio | 1.5 | |||||
| Price-to-Tangible-Book | 2.55 | |||||
| Price-to-Free-Cash-Flow | 11.61 | |||||
| Price-to-Operating-Cash-Flow | 10.54 | |||||
| EV-to-EBIT | 24.01 | |||||
| EV-to-EBITDA | 24.01 | |||||
| EV-to-Revenue | 3.9 | |||||
| EV-to-FCF | 16.35 | |||||
| Price-to-Projected-FCF | 1.35 | |||||
| Price-to-Median-PS-Value | 0.75 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
| Price-to-Graham-Number | 1.85 | |||||
| Price-to-Net-Current-Asset-Value | 9.78 | |||||
| Earnings Yield (Greenblatt) % | 4.16 | |||||
| FCF Yield % | 8.61 | |||||
| Forward Rate of Return (Yacktman) % | 21.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Huaren Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,493.951 | ||
| EPS (TTM) (Â¥) | 0.124 | ||
| Beta | 0.76 | ||
| Volatility % | 28.64 | ||
| 14-Day RSI | 40.62 | ||
| 14-Day ATR (Â¥) | 0.128424 | ||
| 20-Day SMA (Â¥) | 3.8605 | ||
| 12-1 Month Momentum % | -8.29 | ||
| 52-Week Range (Â¥) | 2.77 - 4.35 | ||
| Shares Outstanding (Mil) | 1,182.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Huaren Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Huaren Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Huaren Pharmaceutical Co Ltd Frequently Asked Questions
What is Huaren Pharmaceutical Co Ltd(SZSE:300110)'s stock price today?
The current price of SZSE:300110 is ¥3.52. The 52 week high of SZSE:300110 is ¥4.35 and 52 week low is ¥2.77.
When is next earnings date of Huaren Pharmaceutical Co Ltd(SZSE:300110)?
The next earnings date of Huaren Pharmaceutical Co Ltd(SZSE:300110) is .
Does Huaren Pharmaceutical Co Ltd(SZSE:300110) pay dividends? If so, how much?
The Dividend Yield %  of Huaren Pharmaceutical Co Ltd(SZSE:300110) is 0.58% (As of Today), Highest Dividend Payout Ratio of Huaren Pharmaceutical Co Ltd(SZSE:300110) was 1.71. The lowest was 0.13. And the median was 0.34. The  Forward Dividend Yield % of Huaren Pharmaceutical Co Ltd(SZSE:300110) is 0.58%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers